Consensus Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
4.15 ^USD	+1.22%		+0.48%	-24.55%

05-15	Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	MT
04-30	Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	MT

Evolution of the average Target Price on Marker Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

88e16c2fdef7a2.bduylNSs1ulDD32mQe6VWZjyTOvEluwenuEbKY6g2-M.FY7K3rye5YsTRCjud9mtEKCCFYKDrqUsq6kjTb_qjY8vn8PDmt6SsRVXDg~f518146bf28f05a90a6f222b13c70640

Analyst Recommendations on Marker Therapeutics, Inc.

Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	04-30	MT
Piper Sandler Adjusts Marker Therapeutics' Price Target to $1.50 From $3.50, Reiterates Overweight Rating	22-05-31	MT
Oppenheimer Adjusts Marker Therapeutics' Price Target to $5 From $8, Maintains Outperform Rating	22-02-17	MT
Roth Capital Downgrades Marker Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3	22-02-17	MT
MARKER THERAPEUTICS : Piper Sandler Starts Marker Therapeutics at Overweight with $6 Price Target	21-03-25	MT
MARKER THERAPEUTICS : Cantor Fitzgerald Initiates Marker Therapeutics at Overweight Rating With $6 Price Target	21-03-19	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.15 USD

Average target price

11 USD

Spread / Average Target

+165.06%

High Price Target

11 USD

Spread / Highest target

+165.06%

Low Price Target

11 USD

Spread / Lowest Target

+165.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Marker Therapeutics, Inc.

Ladenburg Thalmann
Piper Sandler
Roth Capital Partners
Oppenheimer
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar